Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657220 | 0.87 | CAMK2D (0.42) | GSK3BCAMK2DRPS6KB1 | |
| SCHEMBL7657255 | 0.86 | MAPT (0.34) | ASH1LMAPTGSK3BQPCTTDP1 | |
| SCHEMBL7664757 | 0.84 | CAMK2D (0.38) | MAPTGSK3BQPCTCAMK2D | |
| SCHEMBL7657012 | 0.84 | MAPT (0.36) | ASH1LMAPTTDP1CAMK2D | |
| Acetic Acid SCHEMBL7663687 | 0.84 | MAPT (0.41) | ASH1LMAPTGSK3BQPCTTDP1 | |
| Acetic Acid SCHEMBL7815326 | 0.84 | MAPT (0.41) | ASH1LMAPTTDP1NPBWR1 | |
| Acetic Acid SCHEMBL8366763 | 0.83 | MAPT (0.38) | ASH1LMAPTGSK3BQPCTTDP1 | |
| SCHEMBL7654136 | 0.83 | EGLN1 (0.39) | CAMK2D | |
| Acetic Acid SCHEMBL7654036 | 0.83 | ASH1L (0.36) | ASH1LMAPTGSK3BQPCTTDP1 | |
| SCHEMBL7664653 | 0.83 | PDE4B (0.38) | GSK3BQPCTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |